ライフサイエンスコーパス: purpura

1 anchored to ECs (thrombotic thrombocytopenic purpura).

2 atients with chronic immune thrombocytopenic purpura.

3 on nucleosome levels in children with septic purpura.

4 es, particularly thrombotic thrombocytopenic purpura.

5 ity and the pathogenesis of Henoch-Schonlein purpura.

6 thogenesis and treatment of Henoch-Schonlein purpura.

7 lter the natural history of Henoch-Schonlein purpura.

8 sis of Kawasaki disease and Henoch-Schonlein purpura.

9 otease, leads to thrombotic thrombocytopenic purpura.

10 hogenesis of chronic immune thrombocytopenic purpura.

11 n bleeding disorder, immune thrombocytopenic purpura.

12 d chronic refractory immune thrombocytopenic purpura.

13 tions for refractory immune thrombocytopenic purpura.

14 atients with chronic immune thrombocytopenic purpura.

15 atients with chronic immune thrombocytopenic purpura.

16 protease, causes thrombotic thrombocytopenic purpura.

17 treatment of chronic immune thrombocytopenic purpura.

18 egnant patients with immune thrombocytopenic purpura.

19 ficient to cause thrombotic thrombocytopenic purpura.

20 plasma leads to thrombotic thrombocytopenic purpura.

21 pproach to childhood immune thrombocytopenic purpura.

22 in the treatment of immune thrombocytopenic purpura.

23 le in idiopathic thrombotic thrombocytopenic purpura.

24 ma-enhanced model of immune thrombocytopenic purpura.

25 hese infections, not immune thrombocytopenic purpura.

26 reating acquired thrombotic thrombocytopenic purpura.

27 mbocytopenia and autoimmune thrombocytopenic purpura.

28 hesion may cause thrombotic thrombocytopenic purpura.

29 lapsing cases of thrombotic thrombocytopenic purpura.

30 ers from that of thrombotic thrombocytopenic purpura.

31 lapsing acquired thrombotic thrombocytopenic purpura.

32 mic syndrome and thrombotic thrombocytopenic purpura.

33 glomerulonephritis, and/or Henoch Schoenlein purpura.

34 lethal syndrome, thrombotic thrombocytopenic purpura.

35 t long-term consequences of Henoch-Schonlein purpura.

36 vasculitides of childhood: Henoch-Schonlein purpura.

37 uired idiopathic thrombotic thrombocytopenic purpura.

38 with idiopathic thrombotic thrombocytopenic purpura.

39 nt management of thrombotic thrombocytopenic purpura.

40 of patients afflicted with Henoch-Schonlein purpura.

41 ctors in the development of Henoch-Schonlein purpura.

42 pathic disorder, thrombotic thrombocytopenic purpura.

43 ADAMTS13 causes thrombotic thrombocytopenic purpura.

44 met criteria for thrombotic thrombocytopenic purpura.

45 oimmune thrombocytopenia and posttransfusion purpura.

46 ce in a model of thrombotic thrombocytopenic purpura.

47 MTS13 that cause thrombotic thrombocytopenic purpura.

48 utoantibodies in thrombotic thrombocytopenic purpura.

49 y experienced in thrombotic thrombocytopenic purpura.

50 eficiency causes thrombotic thrombocytopenic purpura.

51 e sclerosis, and idiopathic thrombocytopenic purpura.

52 ristic for acute thrombotic thrombocytopenic purpura.

53 called acquired thrombotic thrombocytopenic purpura.

54 kin manifestations, including 39 (8.0%) with purpura, 13 (2.7%) with Osler nodes, 8 (1.6%) with Janew

55 spherocytosis (111), immune thrombocytopenic purpura (36), sickle cell disease (SCD) (51), and other

56 Baseline manifestations were purpura (75%), peripheral neuropathy (52%), arthralgia o

57 Thrombotic thrombocytopenic purpura, a clinical syndrome characterized by thrombocyt

58 tinction between thrombotic thrombocytopenic purpura, a disease characterized by a lack of ADAMTS13 a

59 cells and causes thrombotic thrombocytopenic purpura, a disease with similarities to D+HUS, in Adamts

60 e pathophysiology of immune thrombocytopenic purpura, a disorder in which autoantibodies against cell

61 uring therapy of thrombotic thrombocytopenic purpura, a subtype of TMAs often associated with severe

62 Besides studies of Henoch-Schonlein purpura, advances in pediatric vasculitis are few as a r

63 wo patients with thrombotic thrombocytopenic purpura and a healthy person.

64 current research in immune thrombocytopenic purpura and a preview of agents in development are provi

65 hird, studies on thrombotic thrombocytopenic purpura and ADAMTS13-knockout mice suggest that ADAMTS13

66 hrombocytopenia, thrombotic thrombocytopenia purpura and antiphospholipid syndrome.

67 ages 39-50 years who presented with retiform purpura and cutaneous necrosis.

68 (TMA), including thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome, have been reporte

69 nia in patients with immune thrombocytopenia purpura and hepatitis C without the development of an im

70 ed several polymorphisms in Henoch-Schonlein purpura and Kawasaki Disease as well as the association

71 atric vasculitis syndromes, Henoch-Schonlein purpura and Kawasaki disease.

72 pathogenesis of thrombotic thrombocytopenic purpura and other arterial thromboses associated with co

73 mbotic agent for thrombotic thrombocytopenic purpura and other thrombotic conditions.

74 or patients with idiopathic thrombocytopenic purpura and persistent severe thrombocytopenia after spl

75 associated with thrombotic thrombocytopenic purpura and sepsis was revealed by the inverse relations

76 om patients with thrombotic thrombocytopenic purpura and sequence alignment of the ADAMTS13 spacer do

77 ents with refractory immune thrombocytopenic purpura and severe thrombocytopenia with bleeding only i

78 thritis, cancer, thrombotic thrombocytopenic purpura and the Ehlers-Danlos type VIIC and Weill-Marche

79 distinction from thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.

80 Mutations from thrombotic thrombocytopenic purpura and von Willebrand disease provide clues for the

81 EFV in Behcet's disease and Henoch-Schonlein purpura, and A1AT in Wegener's granulomatosis.

82 agnosed with primary immune thrombocytopenic purpura, and are not associated with distinctive clinica

83 tations of IE (Osler nodes, Janeway lesions, purpura, and conjunctival hemorrhages).

84 er pylori-associated immune thrombocytopenic purpura, and Ghevaert et al. describe a specially design

85 symptoms of common disorders, such as senile purpura, and have subtle histologic findings.

86 A nephropathy, Tn syndrome, Henoch-Schonlein purpura, and malignant transformation, all of which are

87 case of possible thrombotic thrombocytopenia purpura, and recovered after therapy with plasmapheresis

88 SERVATIONS A woman in her 30s presented with purpura annularis telangiectodes of Majocchi on the lowe

89 herited and acquired immune thrombocytopenic purpura as well as clinical practice on the initial diag

90 The severe ecchymoses and purpura associated with meningococcal sepsis are usually

91 heumatoid arthritis, immune thrombocytopenic purpura, autoimmune hemolytic anemia, systemic lupus ery

92 ble diagnosis of thrombotic thrombocytopenic purpura between Jan 8, 2004, and Dec 6, 2015, were inclu

93 rtant therapy in thrombotic thrombocytopenic purpura, but clinical data for adjunctive therapies, suc

94 ibility and pathogenesis of Henoch-Schonlein purpura, but there are still significant gaps in our kno

95 uremic syndrome, thrombotic thrombocytopenic purpura, C3GN, and dense deposit disease, which share ph

96 reported for 2.9% of immune thrombocytopenic purpura cases treated with rituximab, but they could not

97 m a rare form of idiopathic thrombocytopenic purpura caused by a GPVI-specific autoantibody that medi

98 lupus erythematosus, immune thrombocytopenic purpura, chronic cold agglutinin disease, IgM-mediated n

99 me patients with thrombotic thrombocytopenic purpura; conversely such deficiency is consistently abse

100 Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-rare thrombomicroangiopathy c

101 with congenital thrombotic thrombocytopenic purpura (cTTP) who cannot cleave VWF multimers because o

102 idate the manifestations of Henoch-Schonlein purpura, determine appropriate treatment of the disease,

103 ng from acquired thrombotic thrombocytopenic purpura develop autoantibodies directed toward the plasm

104 esis of clinical thrombotic thrombocytopenic purpura, especially in relation to ADAMTS13.

105 Thrombotic thrombocytopenic purpura exemplifies how von Willebrand factor can be res

106 is and management of immune thrombocytopenic purpura focused entirely on primary disease, and seconda

107 ears of age, had idiopathic thrombocytopenic purpura for more than 3 months, had a previous splenecto

108 OL) of patients surviving the acute phase of purpura fulminans (PF) has not been evaluated.

109 Purpura fulminans in adults is a rare but devastating di

110 Homozygous deficiency usually manifests as purpura fulminans in infancy and is often fatal.

111 Skin biopsies in purpura fulminans lesions revealed thrombosis and extens

112 Purpura fulminans was a frequent complication, developin

113 Twenty patients with severe sepsis and purpura fulminans were recruited for blood sampling, and

114 d severe deficiency associated with neonatal purpura fulminans.

115 botic local imbalance are characteristics of purpura fulminans.

116 s showed that these lesions were specific to purpura fulminans.

117 ggers the vascular damages that characterize purpura fulminans.

118 Patients with purpura had larger cardiac vegetations (18.1 vs 13.7 mm,

119 most effective treatment of Henoch-Schonlein purpura has begun to emerge.

120 eatment landscape of immune thrombocytopenic purpura has the potential for dramatic change in the nea

121 Studies of Henoch-Schonlein purpura have focused on pathogenesis and outcome.

122 gy of idiopathic thrombotic thrombocytopenic purpura have provided the rationale for immune-based tre

123 of patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is difficult

124 distinction from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome difficult or impossibl

125 of occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy and (

126 Case series of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from 1964 to 2002 were

127 r development of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is near term and durin

128 Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome occurs more commonly i

129 ital or familial thrombotic thrombocytopenic purpura-hemolytic uremic syndrome who were initially dia

130 or occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

131 ecently reported thrombotic thrombocytopenia purpura/hemolytic uremic syndrome (TTP/HUS) case involve

132 er TMAs, such as thrombotic thrombocytopenic purpura; however, novel bioassays are being developed.

133 Although Henoch-Schonlein purpura (HSP) can occur at any age from infancy to adult

134 Henoch Schonlein Purpura (HSP) is the commonest systemic vasculitis of ch

135 sis and treatment of immune thrombocytopenic purpura in children continue to evolve.

136 immune thrombocytopenia and post-transfusion purpura in individuals with the alphaII(B)betaIII 33:Pro

137 esent guidelines for immune thrombocytopenic purpura in pregnancy based on evidence-based data from p

138 associated with thrombotic thrombocytopenic purpura, in which life-threatening episodes of microangi

139 ritish guidelines on immune thrombocytopenic purpura incidence, prevalence, and natural history, with

140 pid syndrome and thrombotic thrombocytopenic purpura, include immunosuppression and systemic anticoag

141 ar changes occurring during Henoch-Schonlein purpura, including cytokines, and endothelial and nitric

142 cute episodes of thrombotic thrombocytopenic purpura, independent of ADAMTS13 activity.

143 ronic refractory idiopathic thrombocytopenic purpura is a dilemma because many patients have minimal

144 The diagnosis of immune thrombocytopenic purpura is a process of elimination of other sources of

145 Thrombotic thrombocytopenic purpura is a rare complication of thienopyridine treatme

146 acquired form of thrombotic thrombocytopenic purpura is associated with inhibitory autoantibodies aga

147 Thrombotic thrombocytopenic purpura is caused by congenital or acquired deficiency o

148 microangiopathy, thrombotic thrombocytopenic purpura is distinguished by a severe deficiency in the A

149 vity in acquired thrombotic thrombocytopenic purpura is due to an autoantibody inhibitor of the von W

150 If the diagnosis of immune thrombocytopenic purpura is in question due to the presence of atypical f

151 Refractory immune thrombocytopenic purpura is infrequent in children, but carries substanti

152 ce and prevalence of immune thrombocytopenic purpura is limited, with nearly all data coming from Eur

153 Childhood Henoch-Schonlein purpura is more frequent in the West Midlands than previ

154 f novel therapies in immune thrombocytopenic purpura is undergoing a revolution that has the potentia

155 Adult-onset Henoch-Schonlein purpura is unusual, but through case studies, this revie

156 eatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction.

157 erican patients with immune thrombocytopenic purpura (ITP) and the effect of H pylori eradication on

158 ytes are targeted by immune thrombocytopenic purpura (ITP) autoantibodies, as are platelets, we have

159 lt patients with idiopathic thrombocytopenic purpura (ITP) for more than 50 years.

160 sis of treatment for immune thrombocytopenic purpura (ITP) has conventionally relied on nonspecific i

161 nesis of chronic idiopathic thrombocytopenic purpura (ITP) involves antibody-mediated platelet destru

162 Idiopathic thrombocytopenic purpura (ITP) is a common hematologic disorder manifeste

163 Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disease caused by platele

164 Adult chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder manifested by th

165 Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet d

166 Chronic immune thrombocytopenic purpura (ITP) is characterized by low platelet counts an

167 Immune thrombocytopenic purpura (ITP) is characterized by the presence of antipl

168 Chronic immune thrombocytopenic purpura (ITP) is manifested by autoantibody-induced plat

169 Although idiopathic thrombocytopenic purpura (ITP) is the most common autoimmune hematologic

170 Patients with severe immune thrombocytopenic purpura (ITP) may require an acute increase in the plate

171 t cytopenias such as immune thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia, mouse mode

172 Treatments for immune thrombocytopenic purpura (ITP) providing durable platelet responses witho

173 eatment strategy for immune thrombocytopenic purpura (ITP) through the use of a mouse model of the di

174 h recently diagnosed immune thrombocytopenic purpura (ITP) who had failed an initial steroid course t

175 diseases, including immune thrombocytopenic purpura (ITP), autoimmune neuropathies, systemic lupus e

176 ytopenia, especially immune thrombocytopenia purpura (ITP), is essential to avoid unnecessary and pot

177 ies with chronic idiopathic thrombocytopenic purpura (ITP), platelet counts less than 30 000 per muL

178 ncluded that, in idiopathic thrombocytopenic purpura (ITP), production of platelets from megakaryocyt

179 ication of childhood immune thrombocytopenia purpura (ITP).

180 eloped in a model of immune thrombocytopenic purpura (ITP).

181 80% of patients with immune thrombocytopenic purpura (ITP).

182 newly diagnosed with immune thrombocytopenic purpura (ITP).

183 95, for treatment of immune thrombocytopenic purpura (ITP).

184 tics associated with immune thrombocytopenic purpura (ITP).

185 t-line treatment for immune thrombocytopenic purpura (ITP).

186 ocytopenia (HIT) and immune thrombocytopenic purpura (ITP).

187 e aware of this distinctive form of necrotic purpura, its associated autoantibodies, and its link to

188 immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targete

189 immune-mediated thrombotic thrombocytopenic purpura (iTTP) patients.

190 immune-mediated thrombotic thrombocytopenic purpura (iTTP).

191 tality in immune thrombotic thrombocytopenic purpura (iTTP).

192 ncy and ethnic variation of Henoch-Schonlein purpura, Kawasaki disease, and rarer vasculitides during

193 eases, including thrombotic thrombocytopenic purpura, manifest much of their pathology through activa

194 A diagnosis of immune thrombocytopenic purpura may be based on an evaluation of the history, ph

195 (n = 2) and immune-mediated thrombocytopenic purpura (n = 1), were possibly related to bevacizumab.

196 itis (SGN) in adults, while Henoch-Schonlein purpura nephritis (HSPN) in children.

197 IgA nephropathy and Henoch-Schonlein purpura nephritis are common glomerular disorders in ped

198 atment protocols for severe Henoch-Schonlein purpura nephritis are mentioned.

199 esis of IgA nephropathy and Henoch-Schonlein purpura nephritis has evolved over the past decade.

200 ildhood IgA nephropathy and Henoch-Schonlein purpura nephritis have the potential for serious morbidi

201 diatric IgA nephropathy and Henoch-Schonlein purpura nephritis, recent data indicate that angiotensin

202 ons in suspected thrombotic thrombocytopenic purpura, new evidence supporting the efficacy and safety

203 al mechanisms of thrombotic thrombocytopenic purpura not only provide a rationale for the previously

204 Two vaccinees presented with purpura of the lower legs; histological findings indicat

205 gement of refractory immune thrombocytopenic purpura often requires multiple agents that may provide

206 of sirolimus, the patient developed palpable purpura on the bilateral lower extremities that resolved

207 c white plaques, which may be accompanied by purpura or fissuring.

208 ascular coagulation, immune thrombocytopenic purpura, or splenic sequestration did not play a discern

209 treatment of chronic immune thrombocytopenic purpura outside a clinical trial.

210 most effective treatment of Henoch-Schonlein purpura, particularly for patients with severe nephritis

211 erature base, The Alder Hey Henoch Schonlein Purpura Pathway was developed, a revised pathway for the

212 d for idiopathic thrombotic thrombocytopenic purpura regardless of ADAMTS13 levels, but more accessib

213 thogenesis and treatment of Henoch-Schonlein purpura remains incomplete.

214 s with inherited thrombotic thrombocytopenic purpura, resulted in a significant reduction of ADAMTS13

215 diseases such as thrombotic thrombocytopenic purpura, sepsis, and diabetes among others.

216 regnant patient with immune thrombocytopenic purpura should be determined based on maternal indicatio

217 aries between types but includes arthralgia, purpura, skin ulcers, glomerulonephritis, and peripheral

218 zumab developed late immune thrombocytopenic purpura that remitted with standard therapy.

219 In thrombotic thrombocytopenic purpura, the clinical impact of ADAMTS13 deficiency caus

220 mark of IgA nephropathy and Henoch-Schonlein purpura, the onset of which often follows infections.

221 astic syndromes, idiopathic thrombocytopenic purpura, thrombocytopenia due to human immunodeficiency

222 Acquired thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are ap

223 major disorders: thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).

224 Thrombotic thrombocytopenic purpura (TTP) and the hemolytic uremic syndrome (HUS) ar

225 cute episodes of thrombotic thrombocytopenic purpura (TTP) appears complete except for minor cognitiv

226 thic, autoimmune thrombotic thrombocytopenic purpura (TTP) by identifying naturally processed A Disin

227 thophysiology of thrombotic thrombocytopenic purpura (TTP) can be explained by the absence of active

228 Thrombotic thrombocytopenic purpura (TTP) has been a mysterious and deadly disease t

229 Thrombotic thrombocytopenic purpura (TTP) in adults is usually caused by autoantibod

230 ims are: to rule thrombotic thrombocytopenic purpura (TTP) in or out, with urgency, using ADAMTS13 ac

231 Thrombotic thrombocytopenic purpura (TTP) is a devastating thrombotic disorder cause

232 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterize

233 Immune-mediated thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder caused by a

234 Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder resulting f

235 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening hematological condit

236 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening illness caused by de

237 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening systemic illness of

238 Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic disorder diagnosed b

239 Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic

240 abine-associated thrombotic thrombocytopenic purpura (TTP) is a rare complication of gemcitabine trea

241 Thrombotic thrombocytopenic purpura (TTP) is an acute, life-threatening thrombotic m

242 Acquired thrombotic thrombocytopenic purpura (TTP) is caused by aggregation of platelets on u

243 Acquired thrombotic thrombocytopenic purpura (TTP) is characterized by thrombocytopenia and m

244 Thrombotic thrombocytopenic purpura (TTP) is primarily caused by immunoglobulin G (I

245 Thrombotic thrombocytopenic purpura (TTP) is the common name for adults with microan

246 Acquired thrombotic thrombocytopenic purpura (TTP) is the consequence of a severe ADAMTS13 de

247 Hereditary thrombotic thrombocytopenic purpura (TTP) may be rare, but it is forever.

248 presentations of thrombotic thrombocytopenic purpura (TTP) or heparin-induced thrombocytopenia (HIT),

249 ving protease implicated in thrombocytopenic purpura (TTP) pathogenesis was identified as ADAMTS13 (a

250 ty in congenital thrombotic thrombocytopenic purpura (TTP) patients is constrained by limitations in

251 In contrast to thrombotic thrombocytopenic purpura (TTP) patients, no aHUS patients demonstrated ul

252 HUS and acquired thrombotic thrombocytopenic purpura (TTP) remain clinical diagnoses, an increased un

253 st patients with thrombotic thrombocytopenic purpura (TTP) survive the acute TTP episode.

254 Pathogenesis of thrombotic thrombocytopenic purpura (TTP) was a mystery for over half a century unti

255 primary cause of thrombotic thrombocytopenic purpura (TTP) whereas overwhelming activation of complem

256 activity causes thrombotic thrombocytopenic purpura (TTP), a life-threatening syndrome for which pla

257 pathogenesis of thrombotic thrombocytopenic purpura (TTP), a life-threatening thrombotic microangiop

258 In thrombotic thrombocytopenic purpura (TTP), a multimeric form of von Willebrand facto

259 In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von

260 ic treatment for thrombotic thrombocytopenic purpura (TTP), but how therapy affects the level of a di

261 cute episodes of thrombotic thrombocytopenic purpura (TTP), but pregnancy outcomes in women who have

262 tening disorder, thrombotic thrombocytopenic purpura (TTP), characterized by platelet-rich thrombi in

263 emonstrated that thrombotic thrombocytopenic purpura (TTP), characterized by widespread thrombosis in

264 transfusions in thrombotic thrombocytopenic purpura (TTP), heparin-induced thrombocytopenia (HIT) an

265 TMAs, especially thrombotic thrombocytopenic purpura (TTP), is difficult due to overlapping clinical

266 openia (ITP) and thrombotic thrombocytopenic purpura (TTP), respectively, illuminate the importance o

267 ndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), the histories and presentations of which

268 In acquired thrombotic thrombocytopenic purpura (TTP), the persistence of severe ADAMTS13 defici

269 g disease called thrombotic thrombocytopenic purpura (TTP).

270 ctivity leads to thrombotic thrombocytopenic purpura (TTP).

271 of ADAMTS13 and thrombotic thrombocytopenic purpura (TTP).

272 fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

273 ng of idiopathic thrombotic thrombocytopenic purpura (TTP).

274 our approach to thrombotic thrombocytopenic purpura (TTP).

275 c and HIV-linked thrombotic thrombocytopenic purpura (TTP).

276 idine-associated thrombotic thrombocytopenic purpura (TTP).

277 associated with thrombotic thrombocytopenic purpura (TTP).

278 protease, causes thrombotic thrombocytopenic purpura (TTP).

279 e development of thrombotic thrombocytopenic purpura (TTP).

280 ts with acquired thrombotic thrombocytopenic purpura (TTP).

281 fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

282 can precipitate thrombotic thrombocytopenic purpura (TTP).

283 nt activation in thrombotic thrombocytopenic purpura (TTP).

284 called acquired thrombotic thrombocytopenic purpura (TTP).

285 ndrome (HUS) and thrombotic thrombocytopenic purpura (TTP).

286 e fatal disorder thrombotic thrombocytopenic purpura (TTP).

287 the symptoms of thrombotic thrombocytopenic purpura (TTP).

288 pathogenesis of thrombotic thrombocytopenic purpura (TTP).

289 s of the disease thrombotic thrombocytopenic purpura (TTP); however, experimental evidence in support

290 e United Kingdom Thrombotic Thrombocytopenic Purpura (UK TTP) Registry with clinical and laboratory d

291 timated annual incidence of Henoch-Schonlein purpura was 20.4 per 100000, and was highest between the

292 n secondary forms of immune thrombocytopenic purpura, when the hematologist plays a consultative role

293 serious underlying pathophysiology, such as purpura, which indicates a bleeding diathesis.

294 re common TMA is thrombotic thrombocytopenic purpura, which is caused by the lack of normal ADAMTS-13

295 Adults with severe thrombocytopenic purpura who responded poorly to therapeutic plasma excha

296 sk of relapse of thrombotic thrombocytopenic purpura will be important to further validate the strate

297 he various complications of Henoch-Schonlein purpura will be reviewed.

298 nts with renal disease from Henoch-Schonlein purpura will be summarized.

299 hat is associated with neutropenia, retiform purpura with cutaneous necrosis and autoantibodies consi

300 nts in patients with immune thrombocytopenic purpura, without significant adverse effects.